Skip to main content

Ponatinib Pregnancy and Breastfeeding Warnings

Ponatinib is also known as: Iclusig

Ponatinib Pregnancy Warnings

This drug should be used during pregnancy only when clearly necessary.

AU TGA pregnancy category: D
US FDA pregnancy category: Not Assigned

Risk Summary: Based on animal studies and its mechanism of action, this drug can cause fetal harm.

-This drug can cause fetal harm when administered to pregnant women.
-Verify the pregnancy status of females of reproductive potential before starting treatment.
-Advise males and females of reproductive potential to use effective contraception during treatment and for 3 weeks after the last dose.

Animal studies have revealed evidence of embryofetal lethality, embryofetal toxicity, and teratogenicity at doses lower than human exposures. This drug may impair fertility in females of reproductive potential. There are no controlled data in human pregnancy.

AU TGA pregnancy category D: Drugs which have caused, are suspected to have caused or may be expected to cause, an increased incidence of human fetal malformations or irreversible damage. These drugs may also have adverse pharmacological effects. Accompanying texts should be consulted for further details.

US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Ponatinib Breastfeeding Warnings

Breastfeeding is not recommended during treatment.

Excreted into human milk: Unknown
Excreted into animal milk: Data not available

-Breast-feeding should be stopped during treatment.
-Do not breast-feed for 6 days following the last dose.
-The drug amount in breastmilk is likely to be low as this drug is more than 99% bound to plasma proteins; however, this drug might accumulate in a nursing infant due to its half-life being about 24 hours.
-The effects on the nursing infant and on milk production are unknown.

See references

References for pregnancy information

  1. "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.
  2. Cerner Multum, Inc. "Australian Product Information." O 0
  3. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

References for breastfeeding information

  1. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL:" ([cited 2013 -]):
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  3. "Product Information. Iclusig (ponatinib)." Ariad Pharmaceuticals Inc, Cambridge, MA.
  4. Cerner Multum, Inc. "Australian Product Information." O 0

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.